At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Abrocitinibdrug
Likely dose
Abrocitinib 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy, Safety, and Tolerability of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin
In Brief
A Phase 2 clinical trial evaluating Abrocitinib for Prurigo Nodularis and 4 related conditions. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The primary objective is to assess the efficacy, safety, and tolerability of Abrocitinib for the treatment of Prurigo Nodularis (PN) or Chronic Pruritus of Unknown Origin (CPUO) in patients experiencing moderate to severe pruritus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrurigo Nodularis, Pruritus, Chronic Pruritus, Chronic Prurigo, Skin Diseases
CountriesUnited States
CollaboratorsDuke University, Pfizer
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedSep 2021
Enrollment StartSep 2021
Primary CompletionJul 2022
TodayJul 2026
First PostedSep 9, 2021
Enrollment StartSep 9, 2021
Primary CompletionJul 11, 2022
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 4.8 years ago
Interventions
Abrocitinibdrug
During the study period, subjects will take one Abrocitinib 200 mg tablet once daily orally. Subjects will be directed to take doses of Abrocitinib at approximately the same time of day.